FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078264406> ?p ?o ?g. }

• W2078264406 endingPage "157" @default.
• W2078264406 startingPage "144" @default.
• W2078264406 abstract "The functional selectivity of WAL 2014 FU with regard to stimulation of the neuronal muscarinic M1 receptor subtype in vitro and in vivo is shown in different receptor preparations, isolated organ models, whole animal testing, and finally humans. From receptor binding experiments in membrane preparations from rat tissues and from Chinese hamster ovary cells expressing human muscarinic receptor subtypes, it can be delineated that the ratio between M1 and M2 (hm1 and hm2) is shifted in favour of the M1 receptor affinity, when compared to several classic muscarinic agonists such as carbachol, arecoline, and oxotremorine. The intermediate GTP-shift of 7.5 for WAL 2014 FU in a M2 muscarinic receptor preparation (rat heart) indicates only partial agonistic activity at this subtype, carbachol (e.g., shows a shift of 51). Moreover, the ratio from agonist to antagonist receptor binding comparing the affinities using [3H]cis-methyldioxolane and [3H]N-methylscopolamine as radioligands, suggests only a partial agonist behaviour at M2 receptors, too. In functional assays in vitro, such as phosphoinositide breakdown measured in cerebral cortex slices from guinea pig brain, WAL 2014 FU is as effective (27.8% compared to carbachol 100%) as arecoline (27.6%), but is more effective than RS 86 (22.1%), oxotremorine (21.6%) or McN-A-343 (14.7%). WAL 2014 FU is about as effective as RS 86 and McN-A-343 in stimulating the secretion of N-acetyl-glucosaminidase from RBL cells transfected with the human m1 receptor subtype. Investigating the proton efflux from CHO cells expressing hm1, hm2, and hm3 muscarinic receptor with cytosensor technology WAL 2014 FU was clearly more effective at human m1 receptors (66.3% compared to carbachol 100%) than at hm3 receptors (18.6%) and showed no measurable effect at hm2 receptor expressing cells. The efficacy in isolated organ preparations and in whole animals has already been reported [Ensinger et al., 1993] and shows the functional selectivity of WAL 2014 FU quite impressively. The general receptor profile of WAL 2014 FU demonstrates a nearly specific interaction with muscarinic receptors, having only weak binding affinity for a1- and nicotinic receptors. Results from pharmacokinetic studies in rats and humans indicate high oral bioavailability (>95% in rats) and very low interindividual variation in plasma levels. Furthermore, good penetration of the blood brain barrier with 2.5- to 3-fold higher concentrations of WAL 2014 FU in brain than in plasma could be measured. The advantageous and stable pharmacokinetic profile of WAL 2014 FU and its functional M1 selectivity establish WAL 2014 FU as a promising candidate for drug treatment of Alzheimer's disease. In addition to its role for symptomatic treatment, WAL 2014 FU may also have a disease-modifying potential because of its stimulatory effects on APPs secretion. Drug Dev. Res. 40:144–157, 1997. © 1997 Wiley-Liss, Inc." @default.
• W2078264406 created "2016-06-24" @default.
• W2078264406 creator A5000724574 @default.
• W2078264406 creator A5006566580 @default.
• W2078264406 creator A5012411008 @default.
• W2078264406 creator A5035445978 @default.
• W2078264406 creator A5051347113 @default.
• W2078264406 creator A5053783892 @default.
• W2078264406 creator A5088386114 @default.
• W2078264406 date "1997-02-01" @default.
• W2078264406 modified "2023-09-27" @default.
• W2078264406 title "WAL 2014 FU (talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease" @default.
• W2078264406 cites W1232060482 @default.
• W2078264406 cites W1537867053 @default.
• W2078264406 cites W1825726719 @default.
• W2078264406 cites W1889236699 @default.
• W2078264406 cites W1955212918 @default.
• W2078264406 cites W1968698871 @default.
• W2078264406 cites W1969473574 @default.
• W2078264406 cites W1969751360 @default.
• W2078264406 cites W1977435533 @default.
• W2078264406 cites W1980398993 @default.
• W2078264406 cites W1982423051 @default.
• W2078264406 cites W1989582849 @default.
• W2078264406 cites W1990543766 @default.
• W2078264406 cites W1994067502 @default.
• W2078264406 cites W1994453614 @default.
• W2078264406 cites W2002376137 @default.
• W2078264406 cites W2004713321 @default.
• W2078264406 cites W2009423131 @default.
• W2078264406 cites W2015957565 @default.
• W2078264406 cites W2016254753 @default.
• W2078264406 cites W2022649017 @default.
• W2078264406 cites W2028569155 @default.
• W2078264406 cites W2032862146 @default.
• W2078264406 cites W2036209909 @default.
• W2078264406 cites W2037807929 @default.
• W2078264406 cites W2042403615 @default.
• W2078264406 cites W2043900119 @default.
• W2078264406 cites W2045289035 @default.
• W2078264406 cites W2052072298 @default.
• W2078264406 cites W2061664301 @default.
• W2078264406 cites W2074631079 @default.
• W2078264406 cites W2075552151 @default.
• W2078264406 cites W2076548347 @default.
• W2078264406 cites W2080335457 @default.
• W2078264406 cites W2088116769 @default.
• W2078264406 cites W2117788878 @default.
• W2078264406 cites W2125638023 @default.
• W2078264406 cites W2133509146 @default.
• W2078264406 cites W2144452828 @default.
• W2078264406 cites W2152850012 @default.
• W2078264406 cites W2166069543 @default.
• W2078264406 doi "https://doi.org/10.1002/(sici)1098-2299(199702)40:2<144::aid-ddr5>3.0.co;2-l" @default.
• W2078264406 hasPublicationYear "1997" @default.
• W2078264406 type Work @default.
• W2078264406 sameAs 2078264406 @default.
• W2078264406 citedByCount "13" @default.
• W2078264406 crossrefType "journal-article" @default.
• W2078264406 hasAuthorship W2078264406A5000724574 @default.
• W2078264406 hasAuthorship W2078264406A5006566580 @default.
• W2078264406 hasAuthorship W2078264406A5012411008 @default.
• W2078264406 hasAuthorship W2078264406A5035445978 @default.
• W2078264406 hasAuthorship W2078264406A5051347113 @default.
• W2078264406 hasAuthorship W2078264406A5053783892 @default.
• W2078264406 hasAuthorship W2078264406A5088386114 @default.
• W2078264406 hasConcept C116289061 @default.
• W2078264406 hasConcept C126322002 @default.
• W2078264406 hasConcept C134018914 @default.
• W2078264406 hasConcept C170493617 @default.
• W2078264406 hasConcept C185592680 @default.
• W2078264406 hasConcept C207723603 @default.
• W2078264406 hasConcept C24998067 @default.
• W2078264406 hasConcept C2778824757 @default.
• W2078264406 hasConcept C2778938600 @default.
• W2078264406 hasConcept C2778988552 @default.
• W2078264406 hasConcept C2779600325 @default.
• W2078264406 hasConcept C33789571 @default.
• W2078264406 hasConcept C47488739 @default.
• W2078264406 hasConcept C58732023 @default.
• W2078264406 hasConcept C71924100 @default.
• W2078264406 hasConcept C86803240 @default.
• W2078264406 hasConcept C98274493 @default.
• W2078264406 hasConceptScore W2078264406C116289061 @default.
• W2078264406 hasConceptScore W2078264406C126322002 @default.
• W2078264406 hasConceptScore W2078264406C134018914 @default.
• W2078264406 hasConceptScore W2078264406C170493617 @default.
• W2078264406 hasConceptScore W2078264406C185592680 @default.
• W2078264406 hasConceptScore W2078264406C207723603 @default.
• W2078264406 hasConceptScore W2078264406C24998067 @default.
• W2078264406 hasConceptScore W2078264406C2778824757 @default.
• W2078264406 hasConceptScore W2078264406C2778938600 @default.
• W2078264406 hasConceptScore W2078264406C2778988552 @default.
• W2078264406 hasConceptScore W2078264406C2779600325 @default.
• W2078264406 hasConceptScore W2078264406C33789571 @default.
• W2078264406 hasConceptScore W2078264406C47488739 @default.
• W2078264406 hasConceptScore W2078264406C58732023 @default.
• W2078264406 hasConceptScore W2078264406C71924100 @default.

• next